$PATH

UiPath CEO Daniel Dines Sells 1.4 Million Shares for $22.5 Million

UiPath CEO Daniel Dines sold 1.4 million shares for $22.5 million on Aug. 19, 2026, at $16.07 per share. He retains a 5% stake. The sale was pre-planned under Rule 10b5-1. UiPath has a $8.1B market cap, $1.7B TTM revenue, and $282.3M TTM net income, with shares up 44% over the past year.

Original reporting
Published Aug 20, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 7:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UiPath CEO Daniel Dines Sells 1.4 Million Shares for $22.5 Million — source image
Decision brief

The 30-second read

$PATHNeutralLow
01

Why it matters

The sale is a routine portfolio adjustment under a pre‑planned 10b5‑1 plan, offering limited new insight for traders.

02

Market read

Insider sale provides modest new data but unlikely to move the stock significantly.

03

What to watch

Potential upcoming dilution or strategic changes not disclosed.

Relevance 5/10Novelty 5/10Timing: post‑transaction Aug 19 2026

Background

Form 4 filing reveals insider transaction details for UiPath (PATH).

Company-level read

Ticker impact

$PATHNeutralMedium confidence
Context

SEC Form 4 disclosed CEO Daniel Dines sold ~1.4 M shares for $22.5 M on Aug 19 2026.

Expected impact

Limited short‑term impact; price likely to remain within current range.

Evidence & confidence

Sale size (~$22 M) is small for a market‑cap of $8 B and represents only 5% of insider stake.

Market effects

RPA sector sees no material shift; insider activity typical.

U.S. market only; no broader regional effect.

Minimal global relevance.

Counterpoint

Some investors may view the sale as a subtle warning despite the 10b5‑1 plan.

Key entities

  • Daniel Dines

    CEO and Chairman of UiPath, insider seller.

  • UiPath, Inc.

    Provider of robotic process automation software.

Related articles

$PATHMedAI 8/10

Analysts Have a Wall of Holds on Figma, UiPath and GitLab but Institutions Are Quietly Loading Up

Analysts have issued 41 Holds across 61 ratings for UiPath, GitLab, and Figma, with consensus targets below current prices for two. Institutions hold 65% to 95% of the float, building positions despite cautious analyst sentiment. UiPath and GitLab have surged 58% and 36% in one month, respectively, exceeding analyst targets. Figma's target aligns with its current price. All three companies reported strong revenue growth in recent quarters.

$PLTRHighAI 9/10

Palantir Rockets 16% After Q2 Blowout; C3.ai, UiPath Sit Out the Rally

Palantir Technologies reported Q2 2026 revenue of $1.94B, up 92.8% YoY, beating $1.81B consensus, and raised FY2026 revenue guidance to about $8.15B. U.S. commercial total contract value reached a record $2.1B. Shares rose about 16% to $145.50 after Deutsche Bank upgraded to Buy with a $200 target; C3.ai and UiPath did not rally.

$PLTRMed

JFrog, Zscaler, Palo Alto Networks, Shopify, and UiPath Shares Are Soaring, What You Need To Know

In Tuesday premarket trading, Palantir’s (PLTR) reported Q2 results and raised full-year revenue outlook drove a broad rally in enterprise software and cybersecurity peers. The article cites Palantir’s 26% jump and links the move to lower Treasury yields after geopolitical de-escalation. It also lists gains for JFrog (FROG), Zscaler (ZS), Palo Alto Networks (PANW), Shopify (SHOP), and UiPath (PATH).

$PATHMed

UiPath (NYSE:PATH) Shares Fall as Q2 Outlook Indicates Reduced ARR Growth

NEW YORK, July 30, 2026, 2:01 p.m. EDT — Shares of UiPath NYSE:PATH declined after the company forecasted slower additions to annualized recurring revenue for the second quarter. The stock dropped 3.3% to $12.18 in early U.S. trading. Initial estimates indicate Q2 guidance suggests net new ARR between $28 million and $33 million. Initial estimate: market value, adjusted for cash, is approximately 2.8 times the projected revenue for fiscal 2027. UiPath shares declined even as U.S.

$PATHMed

PATH Stock Slips As UBS Trims Price Target

UiPath (PATH) shares were up about 7.3% on AI automation optimism, but UBS cut its price target to $12 from $13 while keeping a Neutral rating. Street consensus remains Hold with a mean target near $13.47 versus a price around $10.81. The article also cites UiPath’s annual revenue of about $1.61B and recent quarterly net income of about $22.5M.

$PATHMed

UiPath shares rebound as Wall Street warms to its AI-agent pivot

UiPath shares rebounded about 15% over five days after the company reported its first-quarter GAAP operating profit of $28m and GAAP profit for the first time in a first quarter, following a loss a year earlier. Revenue rose 17% to $418m; annual recurring revenue reached $1.9bn (+12%). UiPath is pivoting to AI agents, including its WorkFusion acquisition.